Drugs / GS-6779
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05770895 | Apr 2023 → Jan 2025 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-11-01 | Gilead Sciences | Results Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease gilead.com ↗
GS-2829 / GS-6779 HBV Therapeutic Vaccine Generates Robust, Polyfunctional, Genotype Cross-Reactive CD8 T Cell Responses Accompanied by High Titers of Anti-HBsAg Antibodies |
All press releases naming this drug 1 release
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-6779 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05770895 ↗ |
| Modality | Vaccine | “Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779” NCT05770895 ↗ |